You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ibuprofen And Pseudoephedrine Hydrochloride, and what generic alternatives are available?

Ibuprofen And Pseudoephedrine Hydrochloride is a drug marketed by Aurobindo Pharma, Perrigo, Aurobindo Pharma Ltd, Contract Pharmacal, and Dr Reddys Labs Ltd. and is included in five NDAs.

The generic ingredient in IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE is ibuprofen; pseudoephedrine hydrochloride. There are sixty-four drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ibuprofen; pseudoephedrine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ibuprofen And Pseudoephedrine Hydrochloride

A generic version of IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE was approved as ibuprofen; pseudoephedrine hydrochloride by DR REDDYS LABS LTD on August 14th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE?
  • What are the global sales for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE?
  • What is Average Wholesale Price for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE?
Summary for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Drug patent expirations by year for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Recent Clinical Trials for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institut für Pharmakologie und Präventive MedizinPhase 1
Pharma Medica Research, Inc.Phase 1
Boehringer IngelheimPhase 1

See all IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE clinical trials

Pharmacology for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents and Regulatory Information for IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE ibuprofen; pseudoephedrine hydrochloride CAPSULE;ORAL 209235-001 Dec 1, 2017 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Contract Pharmacal IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 075588-001 Apr 8, 2002 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Perrigo IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE ibuprofen; pseudoephedrine hydrochloride SUSPENSION;ORAL 076478-001 Nov 5, 2003 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Ltd IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 213565-001 Mar 10, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.